trending Market Intelligence /marketintelligence/en/news-insights/trending/tbthd1ppkwa2a7qh0_s0gw2 content esgSubNav
In This List

Alimera Sciences director to forgo re-election

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Alimera Sciences director to forgo re-election

Glen Bradley does not plan to stand for re-election as director of Alimera Sciences Inc. at the company's 2018 annual meeting of stockholders.

Bradley has served as a board member of the company since 2011.

Alpharetta, Ga.-based Alimera is a pharmaceutical company, dealing in the research, development and commercialization of prescription ophthalmic pharmaceuticals, focusing on diseases affecting the back of the eye or retina.